Due to a production error, the article type of this article mislabeled as Clinical Trial. The correct article type is Study Protocol.
The publisher apologizes for this mistake.
The original version of this article has been updated.
The publisher apologizes for this mistake. The original version of this article has been updated.
Summary
Keywords
cancer, metastasis, colorectal cancer, breast cancer, imipramine, Fascin1, tumor invasion, histology
Citation
Frontiers Production Office (2024) Erratum: Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial. Front. Oncol. 14:1405306. doi: 10.3389/fonc.2024.1405306
Received
22 March 2024
Accepted
22 March 2024
Published
16 April 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2024
Updates
Copyright
© 2024 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.